Tevogen (TVGN) Non-Current Debt (2024 - 2026)
Tevogen's (TVGN) quarterly Non-Current Debt came in at $6.4 million in Q2 2026, up 45.45% on a YoY basis from $4.4 million in Q2 2025, and little changed quarter-over-quarter from $6.4 million in Q1 2026.
Analysis
Tevogen (TVGN) Non-Current Debt (2024 - 2026) Analysis & Trends
Tevogen (TVGN) has reported Non-Current Debt for 3 consecutive years, with $6.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Debt rose 45.45% year-over-year to $6.4 million; the trailing twelve-month figure through Jun 2026 stood at $6.4 million (up 45.45% YoY), and the FY2025 full-year result was $4.4 million, up 340.0% from the prior year.
- Non-Current Debt was little changed at $6.4 million in Q2 2026 per TVGN's latest filing, from $6.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $6.4 million in Q1 2026 and bottomed at $1.0 million in Q4 2024.
- Historically, Non-Current Debt has averaged $4.3 million across 3 years, with a median of $4.4 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt soared 340.0% in 2025, then surged 45.45% in 2026.
- Over 3 years, Non-Current Debt stood at $1.0 million in 2024, then surged by 340.0% to $4.4 million in 2025, then soared by 45.45% to $6.4 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $6.4 million, $6.4 million, and $4.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 586.20 Mn |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | - |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 50.15 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 100.26 Mn |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 93.88 Mn |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 847.62 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | - |
| 10 | Tevogen | 27.76 Mn | 27.76 Mn | - | 6.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.40 Mn |
| Mar 31, 2026 | 6.40 Mn |
| Dec 31, 2025 | 4.40 Mn |
| Sep 30, 2025 | 4.40 Mn |
| Jun 30, 2025 | 4.40 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 1.00 Mn |